|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2005-5-23
|
|
pubmed:abstractText |
Gemcitabine (Gem) is the standard treatment for advanced pancreatic cancer. Given the promising phase II results obtained with the Gem-oxaliplatin (GemOx) combination, we conducted a phase III study comparing GemOx with Gem alone in advanced pancreatic cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AitiniEE,
pubmed-author:AndréTT,
pubmed-author:DucreuxMM,
pubmed-author:FarouxRR,
pubmed-author:GERCOR,
pubmed-author:GISCAD,
pubmed-author:HammenRR,
pubmed-author:LabiancaRR,
pubmed-author:LepertRR,
pubmed-author:LledoGG,
pubmed-author:LouvetCC,
pubmed-author:TaïebJJ,
pubmed-author:ZampinoM GMG,
pubmed-author:ZaniboniAA,
pubmed-author:de GramontAA
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3509-16
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15908661-Adenocarcinoma,
pubmed-meshheading:15908661-Adult,
pubmed-meshheading:15908661-Aged,
pubmed-meshheading:15908661-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15908661-Confidence Intervals,
pubmed-meshheading:15908661-Deoxycytidine,
pubmed-meshheading:15908661-Dose-Response Relationship, Drug,
pubmed-meshheading:15908661-Drug Administration Schedule,
pubmed-meshheading:15908661-Female,
pubmed-meshheading:15908661-Follow-Up Studies,
pubmed-meshheading:15908661-Humans,
pubmed-meshheading:15908661-Male,
pubmed-meshheading:15908661-Maximum Tolerated Dose,
pubmed-meshheading:15908661-Middle Aged,
pubmed-meshheading:15908661-Neoplasm Invasiveness,
pubmed-meshheading:15908661-Neoplasm Staging,
pubmed-meshheading:15908661-Organoplatinum Compounds,
pubmed-meshheading:15908661-Pancreatic Neoplasms,
pubmed-meshheading:15908661-Probability,
pubmed-meshheading:15908661-Proportional Hazards Models,
pubmed-meshheading:15908661-Reference Values,
pubmed-meshheading:15908661-Risk Assessment,
pubmed-meshheading:15908661-Survival Analysis,
pubmed-meshheading:15908661-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
|
|
pubmed:affiliation |
Service d'Oncologie, Hôpital Saint Antoine, 184 rue du Faubourg Saint Antoine, 75571 Paris Cedex 12, France. christophe.louvet@sat.ap-hop-paris.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
